Skip to content
DraconiticResearch
Search Sources API
186,546 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BY-NC 3.0RSC Advances

Targeted nanotherapeutic strategy for melanoma using silk-fibroin based artemisinin nanoparticles

  • Deepinder Sharda1,2
  • Amanpreet Kaur2,3
  • Arnab Pattanayak3
  • Diptiman Choudhury1,2
  1. 1Department of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology Patiala 147004 Punjab India +91-8196949843
  2. 2Thapar Institute of Engineering and Technology-Virginia Tech (USA), Center of Excellence in Emerging Materials, Thapar Institute of Engineering and Technology Patiala Punjab-147004 India
  3. 3Department of Electronics and Communication Engineering, Thapar Institute of Engineering and Technology Patiala 147004 Punjab India
Read full textDOICite

Abstract

Skin cancer is one of the most common cancers in the world, and malignant melanoma is the most aggressive and life-threatening form of skin cancer. It often quickly spreads to other parts of the body and may not always respond well to standard treatments. This calls for the urgent development of more effective and targeted treatment strategies. Protein-based nanoparticles have gained considerable attention in oncology owing to their improved bioavailability, tumour-targeted delivery potential, and reduced systemic toxicity. Silk fibroin, a versatile natural biopolymer, has emerged as a promising drug-delivery platform because of its excellent biocompatibility, biodegradability, and structural adaptability. In the present study, spherical silk fibroin-stabilised artemisinin nanoparticles (SF-ARTNPs) were synthesised and evaluated for their anti-melanoma efficacy. The developed nanoparticles demonstrated enhanced stability, improved aqueous dispersibility, high drug-loading efficiency (86.27 ± 2.05%), and a sustained drug-release profile (84.60 ± 7.29%). In vitro cytotoxicity studies revealed that SF-ARTNPs significantly reduced the viability of A375 melanoma cells to 23.31 ± 4.62% at a concentration of 40 µg mL−1, which is further corroborated by scratch assay results indicating suppressed cell migration. Collectively, these findings suggest that SF-ARTNPs have strong potential as an effective nanotherapeutic platform for treating malignant melanoma.

Related

  1. Superhydrophobic Porous Coordination Polymer-Confined Co3O4 Nanoparticles: A Sustainable Strategy for Electrochemical Water Splitting
    Ravula Nagaraju, Litun Kumar Pradhan, J. N. Behera +1
    ACS omegaPeer-reviewedCC BY-NC-NDFull textGeneral chemistryEurope PMC
  2. Targeted delivery of celastrol and siRNA via macrophage biomimetic nanoparticles for doxorubicin-induced cardiomyopathy therapy
    Qiyu Zhang, Tianyu Guo, Xuna Xue +6
    Materials Today BioPeer-reviewedCC BYFull textMaterials & polymersDOAJEurope PMCPMC
  3. Identification of B-cell maturation antigen (BCMA)-targeting peptides and selective drug delivery to multiple myeloma using peptide-targeted DM1 prodrug-loaded nanoparticles
    Gyoyeon Hwang, Raeleen H Sobetski, Doga E Karakus +2
    Nanoscale advancesPeer-reviewedCC BYFull textMaterials & polymersEurope PMCEurope PMCPMC
  4. Inflammation-triggered andrographolide nanoprodrug platform for lung-targeted delivery and immune homeostasis recovery: A therapeutic strategy against cytokine storm
    Yin Zhou, Jiayi Wang, Yi Chen +5
    Asian Journal of Pharmaceutical SciencesPeer-reviewedCC BY-NC-NDFull textMaterials & polymersDOAJEurope PMCPMC
  5. Macrophage Membrane-Camouflaged Mesoporous Polydopamine Nanoparticles for Targeted Delivery of Apigenin in Sepsis-Induced Acute Lung Injury.
    Yingying Zhang, Lizhen Huang, Hanghang Han +4
    International journal of nanomedicinePeer-reviewedCC BY-NCFull textMaterials & polymersEurope PMC

Cite

BibTeXRIS
BibTeX
@article{sharda2026targeted,
  title = {{Targeted nanotherapeutic strategy for melanoma using silk-fibroin based artemisinin nanoparticles}},
  author = {Deepinder Sharda and Amanpreet Kaur and Arnab Pattanayak and Diptiman Choudhury},
  journal = {RSC Advances},
  year = {2026},
  month = aug,
  doi = {10.1039/d6ra04405k},
  url = {https://doi.org/10.1039/d6ra04405k},
  note = {CC BY-NC 3.0},
}
RIS
TY  - JOUR
TI  - Targeted nanotherapeutic strategy for melanoma using silk-fibroin based artemisinin nanoparticles
AU  - Deepinder Sharda
AU  - Amanpreet Kaur
AU  - Arnab Pattanayak
AU  - Diptiman Choudhury
PY  - 2026
DA  - 2026/08/11
JO  - RSC Advances
DO  - 10.1039/d6ra04405k
UR  - https://doi.org/10.1039/d6ra04405k
AB  - Skin cancer is one of the most common cancers in the world, and malignant melanoma is the most aggressive and life-threatening form of skin cancer. It often quickly spreads to other parts of the body and may not always respond well to standard treatments. This calls for the urgent development of more effective and targeted treatment strategies. Protein-based nanoparticles have gained considerable attention in oncology owing to their improved bioavailability, tumour-targeted delivery potential, and reduced systemic toxicity. Silk fibroin, a versatile natural biopolymer, has emerged as a promising drug-delivery platform because of its excellent biocompatibility, biodegradability, and structural adaptability. In the present study, spherical silk fibroin-stabilised artemisinin nanoparticles (SF-ARTNPs) were synthesised and evaluated for their anti-melanoma efficacy. The developed nanoparticles demonstrated enhanced stability, improved aqueous dispersibility, high drug-loading efficiency (86.27 ± 2.05%), and a sustained drug-release profile (84.60 ± 7.29%). In vitro cytotoxicity studies revealed that SF-ARTNPs significantly reduced the viability of A375 melanoma cells to 23.31 ± 4.62% at a concentration of 40 µg mL−1, which is further corroborated by scratch assay results indicating suppressed cell migration. Collectively, these findings suggest that SF-ARTNPs have strong potential as an effective nanotherapeutic platform for treating malignant melanoma.
SN  - 2046-2069
ER  -